The main purpose of this study is to compare myocardial perfusion imaging using Rubidium-82 PET with Tc-99m-MIBI SPET, in the evaluation of significant Coronary Artery Disease (CAD).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
135
Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use
Maximum dose allowed per injection: 1000 MBq Intravenous Use
University College Hospital London NHS Foundation Trust
London, London, United Kingdom
The specificity of detecting significant coronary artery disease (as defined as being >70% stenosis, on coronary CT angiography)
The primary objective is to compare PET vs. SPET, with the primary outcome being the specificity of detecting significant coronary artery disease (as defined as being \>70% stenosis, on coronary CT angiography).
Time frame: Up to 2 days
Evaluate any difference in the clinical interpretation of the Rubidium-82 PET and Tc-99m-MIBI SPET images.
Time frame: Up to 2 days
Evaluate any difference in "Percentage myocardium" that is hypoperfused, between Rubidium-82 PET and Tc-99m-MIBI SPET.
Time frame: Up to 2 days
Evaluate any difference in image quality, artefacts and interpretative confidence between Rubidium-82 PET and Tc-99m-MIBI SPET.
Time frame: Up to 2 days
Evaluate any adverse events or reactions, during Rubidum-82 or Tc-MIBI administration.
Time frame: Up to 2 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.